YOLFTbeta
Hemostemix Inc

Hemostemix Inc

HEM · V · Healthcare / Biotechnology

0.05CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.05
Open0.045
Day Range0.045 – 0.05
52-Week Range0.04 – 0.125
Volume6.00K
Market Cap12.69M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.03
Dividend Yield0.00%
Beta0.67
50-Day Avg0.0687
200-Day Avg0.071

About

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Thomas A. Smeenk B.A., BA Hons
  • Employees0
  • Headquarters707-7th Avenue SW, Calgary, AB, Canada, T2P 3H6, Canada
  • Websitehttps://hemostemix.com

Leadership

  • Mr. Thomas A. Smeenk B.A., BA HonsCo-Founder, President, CEO & Director · b. 1962
  • Ms. Christina Wu CPAInterim Chief Financial Officer
  • Mr. Peter PavlinVice President of Operations
  • Dr. Fraser C. Henderson Sr., M.D.Chief Medical Officer

Financials

Income Statement

Currency: CAD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000000000
Cost of Revenue0036.88K00-1.69K2.45K1.10K495223--
Gross Profit00-36.88K00--1.69K-2.45K-1.10K-495-223--
Operating Expense1.51M4.32M3.97M3.71M2.81M-4.69M7.47M6.67M4.58M2.16M--
Operating Income-1.51M-4.32M-4.00M-3.71M-2.81M-6.42M-4.70M-7.47M-6.67M-4.58M-2.16M-1.98M-5.63M
EBITDA-1.49M-4.29M-3.97M-3.67M-2.81M-6.64M-4.69M-7.47M-6.67M-4.58M-2.16M-2.00M-4.26M
Net Income-1.54M-4.33M-3.99M-3.78M-3.93M-6.19M-4.87M-7.77M-6.29M-5.24M-2.50M-2.62M-4.71M
R&D285.82K1.56M1.49M828.58K60.26K2.26M2.35M650.05K179.90K622.65K384.89K2.97K2.49M
Interest Expense0002.27K1.14M0104.98K106.05K10.49K350.31K550.08K615.21K453.23K

Balance Sheet

Currency: CAD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets816.85K3.94M796.81K227.11K5.30M1.66M104.28K2.32M563.05K465.35K313.76K991.86K846.90K
Total Liabilities242.98K551.70K622.73K3.69M464.79K1.17M4.15M3.42M5.85M7.23M7.68M8.20M5.82M
Total Equity573.87K3.39M174.08K-3.46M4.84M487.80K-4.05M-1.10M-5.28M-6.77M-7.37M-7.20M-4.97M
Cash351.20K3.31M506.58K34.83K3.96M1.47M24.06K257.95K219.44K135.75K155.42K705.70K682.12K
Total Debt---1.39M--2.06M175.00K1.48M4.13M4.32M--
Net Debt-351.20K-3.31M-506.58K1.36M-3.96M-1.47M2.04M-82.95K1.26M3.99M4.17M4.23M2.92M

Cash Flow

Currency: CAD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.11M-3.13M-3.55M-2.69M-3.21M-2.69M-3.40M-5.98M-3.48M-6.10M-1.50M-1.90M-4.53M
Investing Cash Flow-47.62K-33.21K-23.30K-1.53K-6.14K-6.14K-6.14K------
Financing Cash Flow1.33M6.12M769.51K2.22M7.14M201.65K1.96M6.21M3.27M6.02M1.52M2.45M4.66M
Capital Expenditure50.60K33.21K23.30K1.53K6.14K6.14K6.14K000000
Free Cash Flow-1.16M-3.17M-3.57M-2.69M-3.21M-2.69M-3.41M-5.98M-3.48M-6.10M-1.50M-1.90M-4.53M
FCF to OCF104.57%101.06%100.66%100.06%100.00%100.00%100.18%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateFeb 28, 2013May 31, 2013Aug 31, 2013Nov 30, 2013Feb 28, 2014May 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Aug 30, 2022Nov 29, 2022May 29, 2023Nov 27, 2026
EPS Estimate---------------------------------------
EPS Actual-1.47-0.69-0.33-0.31-0.18-0.74-0.27-0.29-0.30-0.35-0.20-0.19-0.47-0.25-0.15-0.14-0.44-0.06-0.07-0.11-0.11-0.12-0.10-0.09-0.09-0.04-0.01-0.06-0.04-0.12-0.01-0.02-0.02-0.06-0.03-0.02-0.01-0.02-
Surprise---------------------------------------
Timing-----------------------------------Pre-marketAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap12.69M
Enterprise Value17.11M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book27.76
EPS-0.03
Book Value-0.028
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-5.06M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets-534.31%
Shares Outstanding211.44M
Shares Float168.41M
Beta0.67
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 30, 20201:20